Florence Namour

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Florence Namour, Paul M. Diderichsen, Eugène Cox et al. · Clinical Pharmacokinetics · 2015 · 134 citations · Full text

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

Frédéric Vanhoutte, Minodora Mazur, O.I. Voloshyn et al. · Arthritis & Rheumatology · 2017 · 75 citations · Full text

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte et al. · Investigational New Drugs · 2016 · 60 citations · Full text

GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy

Anna Cozzoli, Roberta Francesca Capogrosso, Valeriana Sblendorio et al. · Pharmacological Research · 2013 · 56 citations

Molecular Pharmacology, Muscle Function, Kinesiology +11

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions

Florence Namour, Julie Desrivot, Annegret Van der Aa et al. · Drug Metabolism Letters · 2016 · 56 citations